How You Should Be Choosing Your Stocks
Grab your seat at our complimentary LIVE, interactive masterclass for traders. It’s your chance to finally learn how to pick the right stocks and find the best trades. We’ll also be diving into market forecasting and revealing under-the-radar stocks we believe have significant potential in Q2.
Click here now to join and get access to our forecasting.
Daniel Bradbury, insider at Castle Biosciences

Daniel Bradbury Insider Information

Director of Castle Biosciences
Daniel M. Bradbury has served as a member our board of directors since September 2012, and as chairman of our board of directors since September 2014. Since June 2018, Mr. Bradbury has served as Chief Executive Officer of Equillium, Inc., a publicly traded biotechnology company, where he also served as its President from March 2017 until June 2018. Mr. Bradbury is the founder of, and has served as the managing member of, BioBrit, LLC, a life sciences consulting and investment firm, since September 2012. Mr. Bradbury served as President, Chief Executive Officer and a director of Amylin Pharmaceuticals, Inc. from March 2007 until Amylin’s acquisition by Bristol-Myers Squibb Company in August 2012. Prior to Amylin, Mr. Bradbury worked in marketing and sales for ten years at SmithKline Beecham Pharmaceuticals. Mr. Bradbury serves on the board of directors of numerous private companies and two publicly traded companies, Equillium, Inc. and Intercept Pharmaceuticals, Inc. He previously served on the board of directors of the following publicly traded companies: Corcept Therapeutics, Inc., from 2012 to 2019; Geron Corporation, from 2012 to 2019; and Illumina, Inc. from 2004 to 2017. Mr. Bradbury holds a Bachelor of Pharmacy from Nottingham University and a Diploma in Management Studies from Harrow and Ealing Colleges of Higher Education in the United Kingdom.

What is Daniel Bradbury's net worth?

The estimated net worth of Daniel Bradbury is at least $4.50 million as of May 21st, 2020. Mr. Bradbury owns 208,053 shares of Castle Biosciences stock worth more than $4,504,347 as of May 22nd. This net worth evaluation does not reflect any other assets that Mr. Bradbury may own. Learn More about Daniel Bradbury's net worth.

How do I contact Daniel Bradbury?

The corporate mailing address for Mr. Bradbury and other Castle Biosciences executives is 820 S FRIENDSWOOD DRIVE SUITE 201, FRIENDSWOOD TX, 77546. Castle Biosciences can also be reached via phone at (866) 788-9007 and via email at [email protected] Learn More on Daniel Bradbury's contact information.

Has Daniel Bradbury been buying or selling shares of Castle Biosciences?

Daniel Bradbury has not been actively trading shares of Castle Biosciences during the past quarter. As an example of a recent trade by , 0 shares of the business's stock in a transaction dated Sunday, May 22nd. Learn More on Daniel Bradbury's trading history.

Who are Castle Biosciences' active insiders?

Castle Biosciences' insider roster includes Daniel Bradbury (Director), Jeffrey Eberwein (CEO), Tobin Juvenal (Insider), David Kabakoff (Director), Derek Maetzold (Insider), Kristen Oelschlager (COO), Bernhard Spiess (Insider), Frank Stokes (CFO), and Adam Sussman (Director). Learn More on Castle Biosciences' active insiders.

Are insiders buying or selling shares of Castle Biosciences?

During the last year, Castle Biosciences insiders bought shares 1 times. They purchased a total of 1,160 shares worth more than $21,541.20. During the last year, insiders at the sold shares 46 times. They sold a total of 359,249 shares worth more than $22,241,268.28. The most recent insider tranaction occured on March, 29th when Director Daniel Bradbury sold 8,852 shares worth more than $401,172.64. Insiders at Castle Biosciences own 39.7 % of the company. Learn More about insider trades at Castle Biosciences.

Information on this page was last updated on 3/29/2022.

Daniel Bradbury Insider Trading History at Castle Biosciences

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/29/2022Sell8,852$45.32$401,172.64View SEC Filing Icon  
3/14/2022Sell8,852$38.21$338,234.92View SEC Filing Icon  
2/22/2022Sell8,852$39.02$345,405.04View SEC Filing Icon  
2/9/2022Sell8,852$46.53$411,883.56View SEC Filing Icon  
1/24/2022Sell14,631$35.42$518,230.02View SEC Filing Icon  
1/20/2022Sell15,604$35.26$550,197.04View SEC Filing Icon  
1/18/2022Sell2,470$35.30$87,191.00View SEC Filing Icon  
1/4/2022Sell16,353$43.58$712,663.74View SEC Filing Icon  
11/8/2021Sell5,554$61.21$339,960.34View SEC Filing Icon  
11/4/2021Sell4,446$61.05$271,428.30View SEC Filing Icon  
10/21/2021Sell5,000$62.94$314,700.00View SEC Filing Icon  
10/4/2021Sell5,000$60.93$304,650.00View SEC Filing Icon  
9/21/2021Sell5,000$73.95$369,750.00View SEC Filing Icon  
8/17/2021Sell644$60.02$38,652.88View SEC Filing Icon  
8/3/2021Sell5,000$69.62$348,100.00View SEC Filing Icon  
7/26/2021Sell5,000$66.78$333,900.00View SEC Filing Icon  
7/8/2021Sell5,000$69.56$347,800.00View SEC Filing Icon  
4/7/2021Sell15,000$72.81$1,092,150.00View SEC Filing Icon  
3/24/2021Sell7,500$63.09$473,175.00View SEC Filing Icon  
2/23/2021Sell7,500$79.63$597,225.00View SEC Filing Icon  
1/25/2021Sell7,500$76.94$577,050.00View SEC Filing Icon  
1/12/2021Sell12,113$78.29$948,326.77View SEC Filing Icon  
12/29/2020Sell30,000$69.69$2,090,700.00View SEC Filing Icon  
10/20/2020Sell11,750$49.70$583,975.00View SEC Filing Icon  
9/16/2020Sell3,750$48.38$181,425.00View SEC Filing Icon  
9/2/2020Sell7,500$45.66$342,450.00View SEC Filing Icon  
8/18/2020Sell3,750$43.18$161,925.00View SEC Filing Icon  
8/6/2020Sell3,750$41.34$155,025.00View SEC Filing Icon  
7/21/2020Sell3,750$41.81$156,787.50View SEC Filing Icon  
7/8/2020Sell7,500$41.08$308,100.00View SEC Filing Icon  
6/3/2020Sell3,750$37.01$138,787.50View SEC Filing Icon  
5/21/2020Sell3,750$37.21$139,537.50208,053View SEC Filing Icon  
See Full Table

Daniel Bradbury Buying and Selling Activity at Castle Biosciences

This chart shows Daniel Bradbury's buying and selling at Castle Biosciences by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Castle Biosciences Company Overview

Castle Biosciences logo
Castle Biosciences, Inc., a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma. The company also offers DecisionDx-UM test, a proprietary GEP test that predicts the risk of metastasis for patients with uveal melanoma, a rare eye cancer; DecisionDx-SCC, a proprietary 40-gene expression profile test that uses an individual patient's tumor biology to predict individual risk of squamous cell carcinoma metastasis for patients with one or more risk factors; and DecisionDx DiffDx-Melanoma and myPath Melanoma, a proprietary GEP test to diagnose suspicious pigmented lesions. It offers test services through physicians and their patients. The company was founded in 2007 and is headquartered in Friendswood, Texas.
Read More

Today's Range

Now: $21.65
Low: $20.00
High: $21.76

50 Day Range

MA: $30.55
Low: $18.10
High: $45.99

2 Week Range

Now: $21.65
Low: $17.01
High: $78.92


411,563 shs

Average Volume

413,560 shs

Market Capitalization

$568.53 million

P/E Ratio


Dividend Yield



How You Should Be Choosing Your Stocks
Grab your seat at our complimentary LIVE, interactive masterclass for traders. It’s your chance to finally learn how to pick the right stocks and find the best trades. We’ll also be diving into market forecasting and revealing under-the-radar stocks we believe have significant potential in Q2.
Click here now to join and get access to our forecasting.